IL173253A0 - Polypeptides for inducing a protective immune response against staphylococcus aureus - Google Patents
Polypeptides for inducing a protective immune response against staphylococcus aureusInfo
- Publication number
- IL173253A0 IL173253A0 IL173253A IL17325306A IL173253A0 IL 173253 A0 IL173253 A0 IL 173253A0 IL 173253 A IL173253 A IL 173253A IL 17325306 A IL17325306 A IL 17325306A IL 173253 A0 IL173253 A0 IL 173253A0
- Authority
- IL
- Israel
- Prior art keywords
- polypeptides
- immune response
- response against
- protective immune
- inducing
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48984003P | 2003-07-24 | 2003-07-24 | |
| US52011503P | 2003-11-14 | 2003-11-14 | |
| PCT/US2004/023523 WO2005009379A2 (en) | 2003-07-24 | 2004-07-22 | Polypeptides for inducing a protective immune response against staphylococcus aureus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL173253A0 true IL173253A0 (en) | 2006-06-11 |
Family
ID=34107815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL173253A IL173253A0 (en) | 2003-07-24 | 2006-01-19 | Polypeptides for inducing a protective immune response against staphylococcus aureus |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20060177462A1 (OSRAM) |
| EP (1) | EP1651166B8 (OSRAM) |
| JP (1) | JP2007502101A (OSRAM) |
| KR (1) | KR20060065643A (OSRAM) |
| AT (1) | ATE457737T1 (OSRAM) |
| AU (1) | AU2004258979B2 (OSRAM) |
| BR (1) | BRPI0412799A (OSRAM) |
| CA (1) | CA2532370A1 (OSRAM) |
| CY (1) | CY1110028T1 (OSRAM) |
| DE (1) | DE602004025579D1 (OSRAM) |
| DK (1) | DK1651166T3 (OSRAM) |
| ES (1) | ES2342778T3 (OSRAM) |
| HR (1) | HRP20100240T1 (OSRAM) |
| IL (1) | IL173253A0 (OSRAM) |
| IS (1) | IS8213A (OSRAM) |
| MX (1) | MXPA06000854A (OSRAM) |
| NO (1) | NO20060898L (OSRAM) |
| NZ (2) | NZ544542A (OSRAM) |
| PL (1) | PL1651166T3 (OSRAM) |
| PT (1) | PT1651166E (OSRAM) |
| RU (1) | RU2337108C2 (OSRAM) |
| SI (1) | SI1651166T1 (OSRAM) |
| WO (1) | WO2005009379A2 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| JP2007528217A (ja) * | 2004-02-18 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド |
| KR20070085457A (ko) * | 2004-10-25 | 2007-08-27 | 더 유니버시티 오브 웨스턴 온타리오 | 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법 |
| GB0526038D0 (en) * | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP1982185A4 (en) * | 2006-01-27 | 2010-04-28 | Merck Sharp & Dohme | ON S. AUREUS ORF0657N OBJECTIVE ANTIGEN-BINDING PROTEINS |
| US8124108B2 (en) | 2007-01-24 | 2012-02-28 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus epidermidis |
| EP2374467B1 (en) * | 2007-05-04 | 2013-08-28 | Martin Krönke | Protective staphylococcus aureus vaccine based on cell wall-associated proteins |
| RU2009149294A (ru) * | 2007-05-31 | 2011-07-10 | Мерк энд Ко., Инк. (US) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| CN101951948B (zh) | 2007-08-31 | 2015-12-09 | 芝加哥大学 | 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物 |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| EP2376111A4 (en) | 2008-11-26 | 2013-01-09 | Merck Sharp & Dohme | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS |
| ES2784957T3 (es) | 2009-04-03 | 2020-10-02 | Univ Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SPA) |
| CA3154626A1 (en) * | 2009-04-14 | 2010-10-21 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| AU2010352695B2 (en) | 2009-09-30 | 2014-08-21 | Glaxosmithkline Biologicals S.A. | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| BR112012010223A2 (pt) | 2009-10-30 | 2016-12-06 | Novartis Ag | purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| WO2011113056A1 (en) * | 2010-03-12 | 2011-09-15 | The Trustees Of The University Of Pennsylvania | Methods for preventing and treating staphylococcus aureus colonization, infection, and disease |
| BR112013000097B1 (pt) | 2010-07-02 | 2022-02-01 | The University Of Chicago | Polipeptídeo imunogênico isolado, composição imunogênica e seu uso |
| EP2593133A4 (en) | 2010-07-13 | 2014-11-26 | Merck Sharp & Dohme | STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT |
| EP2638058B1 (en) | 2010-11-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| JP2014525429A (ja) | 2011-09-01 | 2014-09-29 | ノバルティス アーゲー | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物 |
| EP2773370A4 (en) | 2011-10-31 | 2016-09-28 | Merck Sharp & Dohme | PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2451 |
| CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
| MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
| US9376487B2 (en) | 2012-07-10 | 2016-06-28 | Merck Sharp & Dohme Corp. | Protective vaccine based on Staphylococcus aureus SA2493 protein |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| EP1173485A1 (en) * | 1999-05-03 | 2002-01-23 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
| GB0014907D0 (en) * | 2000-06-20 | 2000-08-09 | Univ Sheffield | Antigenic polypeptides |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| WO2002102829A2 (en) * | 2001-06-15 | 2002-12-27 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| CN101979413A (zh) * | 2001-11-12 | 2011-02-23 | 诺沃挪第克公司 | 通过金属离子亲和层析法的肽纯化 |
| DE60230670D1 (de) * | 2001-12-11 | 2009-02-12 | Merck & Co Inc | Staphylococcus aureus exopolysaccharid und verfahren |
| US20080050361A1 (en) * | 2004-10-25 | 2008-02-28 | Heinrichs David E | Staphylococcus aureas specific anti-infectives |
| EP2368570A3 (en) * | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
-
2004
- 2004-07-22 HR HR20100240T patent/HRP20100240T1/hr unknown
- 2004-07-22 SI SI200431389T patent/SI1651166T1/sl unknown
- 2004-07-22 WO PCT/US2004/023523 patent/WO2005009379A2/en not_active Ceased
- 2004-07-22 AU AU2004258979A patent/AU2004258979B2/en not_active Ceased
- 2004-07-22 EP EP04778847A patent/EP1651166B8/en not_active Expired - Lifetime
- 2004-07-22 CA CA002532370A patent/CA2532370A1/en not_active Abandoned
- 2004-07-22 ES ES04778847T patent/ES2342778T3/es not_active Expired - Lifetime
- 2004-07-22 NZ NZ544542A patent/NZ544542A/en not_active IP Right Cessation
- 2004-07-22 JP JP2006521226A patent/JP2007502101A/ja active Pending
- 2004-07-22 DE DE602004025579T patent/DE602004025579D1/de not_active Expired - Lifetime
- 2004-07-22 KR KR1020067001610A patent/KR20060065643A/ko not_active Ceased
- 2004-07-22 RU RU2006105498/13A patent/RU2337108C2/ru not_active IP Right Cessation
- 2004-07-22 NZ NZ570750A patent/NZ570750A/en not_active IP Right Cessation
- 2004-07-22 DK DK04778847.6T patent/DK1651166T3/da active
- 2004-07-22 MX MXPA06000854A patent/MXPA06000854A/es active IP Right Grant
- 2004-07-22 BR BRPI0412799-4A patent/BRPI0412799A/pt not_active Application Discontinuation
- 2004-07-22 PT PT04778847T patent/PT1651166E/pt unknown
- 2004-07-22 AT AT04778847T patent/ATE457737T1/de active
- 2004-07-22 US US10/564,458 patent/US20060177462A1/en not_active Abandoned
- 2004-07-22 PL PL04778847T patent/PL1651166T3/pl unknown
-
2005
- 2005-12-30 IS IS8213A patent/IS8213A/is unknown
-
2006
- 2006-01-19 IL IL173253A patent/IL173253A0/en unknown
- 2006-02-23 NO NO20060898A patent/NO20060898L/no not_active Application Discontinuation
-
2010
- 2010-04-30 US US12/771,345 patent/US20100247561A1/en not_active Abandoned
- 2010-05-14 CY CY20101100419T patent/CY1110028T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE457737T1 (de) | 2010-03-15 |
| BRPI0412799A (pt) | 2006-09-26 |
| DE602004025579D1 (de) | 2010-04-01 |
| US20100247561A1 (en) | 2010-09-30 |
| PT1651166E (pt) | 2010-04-23 |
| AU2004258979A1 (en) | 2005-02-03 |
| SI1651166T1 (sl) | 2010-06-30 |
| EP1651166B8 (en) | 2010-05-19 |
| ES2342778T3 (es) | 2010-07-14 |
| MXPA06000854A (es) | 2006-03-30 |
| RU2006105498A (ru) | 2006-09-10 |
| DK1651166T3 (da) | 2010-05-31 |
| EP1651166A2 (en) | 2006-05-03 |
| NZ544542A (en) | 2009-01-31 |
| AU2004258979B2 (en) | 2007-12-06 |
| CY1110028T1 (el) | 2015-01-14 |
| IS8213A (is) | 2005-12-30 |
| RU2337108C2 (ru) | 2008-10-27 |
| WO2005009379A3 (en) | 2006-11-30 |
| PL1651166T3 (pl) | 2010-08-31 |
| NO20060898L (no) | 2006-04-24 |
| KR20060065643A (ko) | 2006-06-14 |
| WO2005009379A2 (en) | 2005-02-03 |
| US20060177462A1 (en) | 2006-08-10 |
| EP1651166A4 (en) | 2008-03-05 |
| EP1651166B1 (en) | 2010-02-17 |
| CA2532370A1 (en) | 2005-02-03 |
| NZ570750A (en) | 2009-12-24 |
| JP2007502101A (ja) | 2007-02-08 |
| HRP20100240T1 (hr) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173253A0 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| WO2005079315A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| ATE462006T1 (de) | Isoform des vegfs | |
| BRPI0517493A (pt) | polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo | |
| DK1649023T3 (da) | Polypeptid med forbedret cytosindeaminaseaktivitet | |
| ATE419359T1 (de) | Cdc27-homologe aus arabidopsis thaliana | |
| WO2005115113A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| WO2007001361A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| WO2006033918A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| WO2005086663A3 (en) | Polypeptides for inducing a protective immune response against staphlococcus aureus | |
| WO2006078680A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| BR9407693A (pt) | Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto | |
| WO2003024992A3 (en) | HUMAN AND MOUSE β-DEFENSINS, ANTIMICROBIAL PEPTIDES | |
| WO2003090667A3 (fr) | Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16 | |
| DE50213015D1 (de) | Lipase-varianten | |
| WO2008115415A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus epidermidis | |
| PH12013502021A1 (en) | Platelet aggregation inhibitor composition | |
| DK1005487T3 (da) | Ydre 74 kD-membranprotein fra Moraxella catarrhalis | |
| WO2007018482A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| WO2006121664A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| ATE452970T1 (de) | N-desoxyribosyltransferase aus lactobacillus, entsprechende nukleinsäuren darauf und ihre verwendungen | |
| CA2530731A1 (en) | Peptide having apoptosis-inhibiting activity | |
| WO2005005469A3 (en) | Novel purified polypeptides from staphylococcus aureus | |
| FR2874025B1 (fr) | Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a legionella pneumophila | |
| WO2003066849A3 (en) | Novel purified polypeptides from staphylococcus aureus |